Skip to main content
Premium Trial:

Request an Annual Quote



Lentigen Licenses ZGene Technology

Lentigen said this week that it has taken an exclusive license from ZGene to certain specified proprietary ZGene multisubstrate kinase genes for certain indications.

These genes will allow Lentigen to create lentiviral vectors with increased safety by providing the capability to eliminate genetically modified cells from the body, if required, the company said.

ZGene will receive an undisclosed upfront payment and stands to receive milestones based on development and commercialization goals, as well as royalties. Additional terms of the deal were not disclosed.